Novartis AG Income from Discontinued Operations 2010-2024 | NVS
Novartis AG annual/quarterly income from discontinued operations history and growth rate from 2010 to 2024. Income from discontinued operations can be defined as income or loss from the complete discontinuation of a segment or business, net of associated taxes and fees.
- Novartis AG income from discontinued operations for the quarter ending June 30, 2024 was $M, a 100% decline year-over-year.
- Novartis AG income from discontinued operations for the twelve months ending June 30, 2024 was $6.092B, a 455.84% increase year-over-year.
- Novartis AG annual income from discontinued operations for 2023 was $6.282B, a 593.38% increase from 2022.
- Novartis AG annual income from discontinued operations for 2022 was $0.906B, a INF% increase from 2021.
- Novartis AG annual income from discontinued operations for 2021 was $0B, a NAN% decline from 2020.
Novartis AG Annual Income from Discontinued Operations
(Millions of US $) |
| 2023 |
$6,282 |
| 2022 |
$906 |
| 2021 |
$ |
| 2020 |
$ |
| 2019 |
$4,590 |
| 2018 |
$-186 |
| 2017 |
$ |
| 2016 |
$ |
| 2015 |
$10,766 |
| 2014 |
$-447 |
| 2013 |
$-17 |
| 2012 |
$-147 |
| 2011 |
$ |
| 2010 |
$ |
| 2009 |
$ |
Novartis AG Quarterly Income from Discontinued Operations
(Millions of US $) |
| 2024-06-30 |
|
| 2024-03-31 |
|
| 2023-12-31 |
$5,842 |
| 2023-09-30 |
$250 |
| 2023-06-30 |
$46 |
| 2023-03-31 |
$144 |
| 2022-12-31 |
$661 |
| 2022-09-30 |
$245 |
| 2022-06-30 |
|
| 2022-03-31 |
|
| 2021-12-31 |
|
| 2021-09-30 |
|
| 2021-06-30 |
|
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| 2020-03-31 |
|
| 2019-12-31 |
|
| 2019-09-30 |
|
| 2019-06-30 |
$4,691 |
| 2019-03-31 |
$-101 |
| 2018-12-31 |
$-26 |
| 2018-09-30 |
$-258 |
| 2018-06-30 |
$40 |
| 2018-03-31 |
$58 |
| 2017-12-31 |
|
| 2017-09-30 |
|
| 2017-06-30 |
|
| 2017-03-31 |
|
| 2016-12-31 |
|
| 2016-09-30 |
|
| 2016-06-30 |
|
| 2016-03-31 |
|
| 2015-12-31 |
$2 |
| 2015-09-30 |
$83 |
| 2015-06-30 |
$-18 |
| 2015-03-31 |
$10,699 |
| 2014-12-31 |
$-961 |
| 2014-09-30 |
$138 |
| 2014-06-30 |
$-138 |
| 2014-03-31 |
$514 |
| 2013-12-31 |
$-83 |
| 2013-09-30 |
$105 |
| 2013-06-30 |
$-39 |
| 2013-03-31 |
|
| 2012-12-31 |
|
| 2012-09-30 |
|
| 2012-06-30 |
|
| 2012-03-31 |
|
| 2011-12-31 |
|
| 2011-09-30 |
|
| 2011-06-30 |
|
| 2011-03-31 |
|
| 2010-12-31 |
|
| 2010-09-30 |
|
| 2010-06-30 |
|
| 2010-03-31 |
|
| 2009-12-31 |
|
| 2009-09-30 |
|
| 2009-06-30 |
|
| 2009-03-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$232.546B |
$45.440B |
|
Novartis has one of the strongest and broadest portfolio of oncology drugs and generics. It continues to build depth in 5 core therapeutic areas Cardio-Renal, Immunology, Neuroscience, Oncology and Hematology, strength in technology platforms - Targeted Protein Degradation, Cell Therapy, Gene Therapy, Radioligand Therapy, and xRNA. Novartis efforts to strengthen its wide and deep oncology portfolio by developing breakthrough treatments. Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio. In March 2015, Novartis acquired certain oncology products and pipeline compounds from Glaxo. In exchange, it sold its non-influenza Vaccines business to Glaxo. Also, the company has spun off the Alcon business into a separate company. In January 2015, Novartis divested its Animal Health division to Lilly. In July 2015, the company divested its influenza vaccines business to CSL Limited. Novartis has also acquired The Medicines Company, adding Leqvio, to its portfolio. Novartis sold its investment in Roche.
|
